Kazia Therapeutics
KZIA
23 hedge funds and large institutions have $13M invested in Kazia Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
5% more funds holding
Funds holding: 22 → 23 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less capital invested
Capital invested by funds: $17.1M → $13M (-$4.02M)
132.95% less ownership
Funds ownership: 148.42% → 15.47% (-133%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.34M |
| 2 |
FLPIM
F.L. Putnam Investment Management
Lynnfield,
Massachusetts
|
+$992K |
| 3 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$556K |
| 4 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$418K |
| 5 |
WIM
Westside Investment Management
Santa Monica,
California
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.09M |
| 2 |
EAM
Empery Asset Management
New York
|
-$1.17M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$1.15M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$802K |
| 5 |
CCM
Corsair Capital Management
New York
|
-$470K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
26
Corsair Capital Management
New York
| – | -$470K | -70,000 | Closed |
|
|
EGM
27
Engineers Gate Manager
New York
| – | -$71.6K | -10,388 | Closed |
|
|
AAP
28
Arax Advisory Partners
Denver,
Colorado
| – | -$1.38K | -200 | Closed |
|
29
Citigroup
New York
| – | -$7 | -1 | Closed |
|
KZIA Hedge Fund Activity: Q1 2026 in Review
23 of the 8,143 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q1 2026, worth a combined $13M — down 24% from $17.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new KZIA positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.34M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $5.09M sold.
- 23 institutional investors held Kazia Therapeutics (KZIA) as of Q1 2026, up from 22 in Q4 2025.
- Funds reported $13M of Kazia Therapeutics stock for Q1 2026, down 24% quarter-over-quarter.
- 7 funds opened new Kazia Therapeutics positions in Q1 2026 and 6 closed out, a net change of +1 holder.
- The largest Kazia Therapeutics buyer in Q1 2026 was Balyasny Asset Management, an estimated $1.34M added.
- The largest Kazia Therapeutics seller in Q1 2026 was Alyeska Investment Group, an estimated $5.09M sold.
Based on aggregated 13F filings for Q1 2026.